Skip to main content
main-content

01.02.2013 | Basic Neurosciences, Genetics and Immunology - Original Article | Ausgabe 2/2013

Journal of Neural Transmission 2/2013

Comparative evaluation of the potency and antigenicity of two distinct BoNT/A-derived formulations

Zeitschrift:
Journal of Neural Transmission > Ausgabe 2/2013
Autoren:
M. Brown, G. Nicholson, M. C. Ardila, A. Satorius, R. S. Broide, K. Clarke, T. Hunt, J. Francis

Abstract

IncobotulinumtoxinA (Xeomin®) and onabotulinumtoxinA (BOTOX®) are unique botulinum neurotoxin type A (BoNT/A)-derived drugs. IncobotulinumtoxinA utilizes the naked 150 kDa holotoxin portion of BoNT/A, whereas onabotulinumtoxinA uses the complete native 900 kDa complex as drug substance. On the basis of purportedly similar pharmacological characteristics, these formulations were evaluated for potency by LD50 and mouse Digit Abduction Score (DAS) bioassays. DAS was also used to assess antigenicity. Full-range DAS dose–response profiles were achieved with four lots of each product, with similar observations between lots for a given product. Between products, however, the mean DAS potency of incobotulinumtoxinA (ED50 range 7.0–10.2 U/kg) was significantly lower than that of onabotulinumtoxinA (ED50 range 4.4–6.4 U/kg), consistent with lower measured potencies in the LD50 assay for incobotulinumtoxinA (potency range 62–82 U). In assessments of DAS duration of effect at similar unit doses, the observed lower potency of incobotulinumtoxinA translated into decreased peak efficacy and dose effect over time (i.e. shorter duration). In contrast, at equi-efficacious doses yielding near-maximal DAS responses, both toxin formulations were uniformly inhibited in a statistically significant manner when preincubated with rabbit-derived, onabotulinumtoxinA-neutralizing antibodies, supporting the position that inhibition of 150 kDa holotoxin serves as the common basis for neutralization and, therefore, incobotulinumtoxinA would not be expected to be effective in onabotulinumtoxinA-immunoresistant subjects (and vice versa). Further, with lower lot-to-lot relative potency, incobotulinumtoxinA is not dose-equivalent or interchangeable with onabotulinumtoxinA, suggesting that various aspects of drug product formulation may influence observed pharmacology.

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

★ PREMIUM-INHALT
e.Med Interdisziplinär

Für Ihren Erfolg in Klinik und Praxis - Die beste Hilfe in Ihrem Arbeitsalltag als Mediziner

Mit e.Med Interdisziplinär erhalten Sie Zugang zu allen CME-Fortbildungen und Fachzeitschriften auf SpringerMedizin.de.

Jetzt e.Med zum Sonderpreis bestellen!

Weitere Produktempfehlungen anzeigen
Literatur
Über diesen Artikel

Weitere Artikel der Ausgabe 2/2013

Journal of Neural Transmission 2/2013 Zur Ausgabe

Neurology and Preclinical Neurological Studies - CONy Pro/Con debate

Why antiplatelet treatment in spontaneous internal carotid dissection?

Neurology and Preclinical Neurological Studies - CONy Pro/Con debate

Is there room for non-dopaminergic treatment in Parkinson disease?

Neurology and Preclinical Neurological Studies - CONy Pro/Con debate

Steroids in bacterial meningitis: yes

Basic Neurosciences, Genetics and Immunology - Original Article

Long-term decrease in immediate early gene expression after electroconvulsive seizures

Neurology and Preclinical Neurological Studies - CONy Pro/Con debate

Anticoagulants versus antiplatelet drugs for cervical artery dissection: case for anticoagulants

  1. Sie können e.Med Neurologie & Psychiatrie 14 Tage kostenlos testen (keine Print-Zeitschrift enthalten). Der Test läuft automatisch und formlos aus. Es kann nur einmal getestet werden.

  2. Sie können e.Med Neurologie 14 Tage kostenlos testen (keine Print-Zeitschrift enthalten). Der Test läuft automatisch und formlos aus. Es kann nur einmal getestet werden.

Neu in den Fachgebieten Neurologie und Psychiatrie